KT102

**KT102** is an investigational **small-molecule** drug candidate reported to be developed by **Keren Therapeutics** for **sarcopenia**. Publicly accessible information on this program is extremely limited; available pipeline intelligence sources identify it as a chemical drug in preclinical development for sarcopenia, but do not disclose a validated molecular target, detailed mechanism of action, formulation, or route of administration. Based on the sparse source record, it appears to be a pharmaceutical R&D code rather than a marketed product, and any more specific claims about target biology or modality subclass would be speculative.